Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$565.52 USD

565.52
61,782

-2.85 (-0.50%)

Updated May 17, 2024 04:00 PM ET

After-Market: $565.00 -0.52 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Fresenius Medical (FMS) Q2 Earnings Beat Estimates, Up Y/Y

by Zacks Equity Research

Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.

Chemed (CHE) Q2 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

Chemed (CHE) reports better-than-expected earnings and revenues with strong Roto-Rooter segment performance driving the top line in second-quarter 2021.

Chemed (CHE) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 3.37% and 0.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Chemed (CHE) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Chemed (CHE) Up 4.7% Since Last Earnings Report?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Trina Mukherjee headshot

3 Stocks to Bank on Rebounding Outpatient Home Health Industry

by Trina Mukherjee

Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well-poised to gain from the prospects.

EHC or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EHC vs. CHE: Which Stock Is the Better Value Option?

ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up

by Zacks Equity Research

Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.

What's in Store for Fulgent Genetics' (FLGT) Q1 Earnings?

by Zacks Equity Research

COVID-19 testing and NGS-based testing solutions are expected to have contributed to Fulgent Genetics' (FLGT) Q1 earnings.

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.

EHC or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EHC vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Q1 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Chemed's (CHE) first-quarter 2021 revenues increase year-over-year on solid growth across its Roto-Rooter arm.

Chemed (CHE) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 5.71% and 2.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid

by Zacks Equity Research

The federal government's recent approach in terms of relaxing regulations, allowing broader use of telehealth, is likely to have helped in some sort of recovery of Chemed's (CHE) VITAS business in Q1.

Moving Average Crossover Alert: Chemed Corp (CHE)

by Zacks Equity Research

Chemed Corporation (CHE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Why Is Chemed (CHE) Down 2.6% Since Last Earnings Report?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Chemed (CHE) Q4 Earnings Miss Estimates, 2021 Outlook Dull

by Zacks Equity Research

Chemed's (CHE) fourth-quarter 2020 revenues increased 2.1% year over year to $533.3 million.

Trina Mukherjee headshot

3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn

by Trina Mukherjee

Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well positioned to gain from the prospects.

    DVA vs. CHE: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    DVA vs. CHE: Which Stock Is the Better Value Option?

    Align (ALGN) Rides on Robust Invisalign Sales Amid Coronavirus

    by Zacks Equity Research

    Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.

    CVS Health's (CVS) Front Store Sales Robust, LTC Suffers

    by Zacks Equity Research

    CVS Health's (CVS) Health Care Benefits arm benefits from strong Medicare annual enrollment period.

    Quest Diagnostics (DGX) Ties Up With Hackensack Meridian Health

    by Zacks Equity Research

    Quest Diagnostics (DGX) collaborates with Hackensack Meridian Health to manage laboratory operation and provide high-quality healthcare network.

    Here's Why You Should Hold onto NEOGEN (NEOG) Stock for Now

    by Zacks Equity Research

    Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

    Encompass Health (EHC) to Spin Off Unit to Streamline Business

    by Zacks Equity Research

    Encompass Health (EHC) is exploring strategic alternatives to split its home health and hospice business from the original corporate structure to streamline operations.